对于肿瘤学学术进展随者来说，Asco摘要的发布是一年中最大的事件之一，尽管连续第二年进行虚拟化，但2021年看起来仍将提供重要更新的一部分。梅斯医学将带领大家了解最近进展~ENJOY!

然而，许多最重要的数据仍处于保密状态，最新的摘要将于6月3日美国东部时间下午5点（会议召开的前一天）发布。

重要的Asco最新摘要节选

 

重点关注的Asco最新摘要结果预告节选1：

阿斯利康/默沙东Lynparza(利普卓)（Merck＆Co Lynparza Olympia）：PH（3）辅助化疗后，Lynparza在种系BRCA1 / 2突变和高风险HER2阴性早期乳腺癌中进行（新）辅助化疗后的试验 默沙东Keynote-564：Keytruda作为肾切除术后辅助治疗肾细胞癌的ph3试验 诺华177Lu-PSMA-617：177Lu-PSMA-617在转移性去势抵抗性前列腺癌中的第3期临床试验 君实生物和Coherus Biosciences 拓益Jupiter-02：拓益（toripalimab）联合化学治疗复发或转移性鼻咽癌的一线治疗的ph3试验 BMS Opdivo和Yervoy Checkmate-648：Opdivo加Yervoy等化学疗法作为晚期食道鳞状细胞癌的一线治疗CheckMate 648研究的第一项结果。重要精选摘要目录：

重要精选摘要目录
公司	项目	药物作用机制	摘要序列号	题目概述
Adaptimmune	Afami-cel	Anti-Mage-A4 eTCR	11504	Adaptimmune’s T-cell receptors see a route to market
Alkermes	Nemvaleukin	IL-2 mimic	2513	Responses seen in monotherapy and with Keytruda across various tumours
Allogene	ALLO-501	Anti-CD19 allo Car-T	2529	Off-the-shelf cell therapy inches towards reality
Alpine Immune	ALPN-202	Conditional CD28 costimulator and dual checkpoint inhibitor	2547	Ph1 dose escalation; 1 unconfirmed PR and 5 SD in 11 subjects
Arcus	Etrumadenant + zimberelimab + AB680	A2aR/A2bR antagonist + anti-PD-1 + anti-CD73	5039	In evaluable pts, PSA response 5/14, radiographic response 3/8, with 1 CR, composite response rate was 43% (6/14)
Black Diamond	BDTX-189	EGFR/HER2 kinase inhibitor	3086	Of 15 evaluable, 1 confirmed PR, 3 SD and 10 progressive disease
Bristol Myers Squibb	Relatlimab	Anti-Lag3 MAb	9503	Bristol’s Lag3 case for a replacement for Yervoy
Cullinan	CLN-081	EGFR Exon20 inhibitor	9077	Of 25 evaluable, 10 PRs, 14 SD, 1 progressive disease. Later cut to be presented
G1	Rintodestrant	SERD	1063	Ph1 safety data: rintodestrant-related AEs in 8%, all grade 2
I-Mab	Uliledlimab	Anti-CD73 MAb	2511	Of 13 evaluable, 3 CRs or PRs (ORR 23%) and 3 SD (disease control rate 46%).
Immunogen	Mirvetuximab	Anti-FRα ADC	5504	Of 33 pts with high FRα expression ORR 64%, mDOR of 11.8 months, and mPFS of 10.6 months (Forward I study failed in all-comers)
Immutep	eftilagimod alpha	Lag3	9046; 6028; 2518	Data from ongoing Ph2 trials in combination with Keytruda (NSCLC & H&N), and Ph1 plus Bavencio.
Kadmon	KD033	Anti-PD-L1/IL-15 fusion protein	2568	Of 6 evaluable, 1 SD
Macrogenics	MGC018	Anti-B7-H3 ADC	2631	3 unconfirmed PRs in melanoma pts
Merus	Zenocutuzumab	Anti-Her2/Her3 bispecific	3003	Merus intrigues in pancreatic cancer
Roche	Tecentriq	Anti-PD-L1 MAb	8500	Adjuvant lung cancer beckons for Tecentriq, but only in PD-L1 expressers
SQZ Biotechnologies	SQZ-PBMC-HPV-101	T-cell surface glycoprotein CD8 stimulant	2536	4 SD in 10 evaluable pts
Sutro	STRO-002	FRα inhibitor	5550	Of 31 evaluable, 1 CR, 4 confirmed PR, and 5 unconfirmed PR. Disease control rate was 74% at 12 weeks and 61% at 16 weeks.
Sensei	SNS-301	ASPH targeted bacteriophage	6029	67% response rate in 12 PD-1 refractory H&N patients
PDS Biotech	PDS0101	HPV targeted T cell activator	2501	In combination with M9241 and bintrafusp alpha, ORR of 71%

当然，这还远远没有详尽地介绍重要的口头演讲，并且在接下来的几周内将有更多的数据发布，尽请保持关注！

更多内容关注梅斯医学ASCO专题页：https://meeting.medsci.cn/ASCO2020

参考来源：https://meetinglibrary.asco.org/results?meetingView=2021%20ASCO%20Annual%20Meeting